NeuroSAFE remains an investigational, debatable, laborious (expensive) procedure
André N. Vis, Jakko A. Nieuwenhuijzen, Hans Veerman, Ton A. Roeleveld, Esther Wit, Tim M. van der Sluis, Henk G. van der Poel, Pim J. van Leeuwen
Abstract
programme which could be relied upon to detect these patients later, then perhaps we could be less concerned.However, we do not.Further, a holistic clinical judgement as to whether investigation or treatment is to be of benefit for any patient is best.This is especially true in the age group 70-79 years.Tradition dictates these patients are too old to benefit from curative treatment.However, many of these patients remain in good health and have more than a decade of life expectancy.Ultimately, making these decisions requires a referral and, clearly, these new criteria do not encourage that.Thus, we would recommend maintaining lower PSA referral levels.